We investigated the efficacy and tolerability of a fixed low-dose combination of once-daily metoprolol succinate 95mg (slow-release Zok) plus hydrochlorothiazide (HCTZ) 12.5mg in daily practice.
A number of comparative studies have been performed with metoprolol, a β 1-selective "second-generation" β blocker, and carvedilol, a nonselective and vasodilatative "third-generation" β blocker.
There is evidence to indicate that full adrenergic blockade by carvedilol improves survival and cardiovascular outcome in patients with heart failure compared with metoprolol treatment ...